Overview

Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), in healthy male and female adult volunteers. Safety of E004 will also be evaluated, under augmented dose conditions.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Amphastar Pharmaceuticals, Inc.
Treatments:
Epinephrine
Epinephryl borate
Racepinephrine